
Amphastar Pharma (AMPH) Stock Forecast & Price Target
Amphastar Pharma (AMPH) Analyst Ratings
Bulls say
Amphastar Pharmaceuticals Inc. has demonstrated notable sales momentum, particularly with Baqsimi, which experienced approximately a 20% quarter-over-quarter increase in prescriptions during the third quarter of 2025, aided by collaboration with MNKD and seasonal trends. The company anticipates maintaining a flat year-over-year top line in 2025, followed by a projected return to double-digit growth in 2026, underpinned by expectations of high-single digit unit growth for its products. Additionally, the strong performance of Primatene Mist in the third quarter positions the company to benefit from seasonal demand, contributing positively to its overall financial outlook.
Bears say
Amphastar Pharmaceuticals Inc. is facing significant challenges in its product portfolio, particularly with iron sucrose and glucagon, which are expected to generate much lower sales than previously anticipated, with projections of under $70 million for glucagon starting in 2026. Increased competition in the market has impacted the sales estimates for these products significantly, with iron sucrose's sales now forecasted around $5 million per quarter and glucagon sales anticipated to trend down further. The company's outlook for growth has been moderated from double-digit expectations to a range of high-single to low-double digits due to pressures from a competitive landscape and pipeline limitations.
This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares